Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. J of Skin [Internet]. 2018 Feb. 23 [cited 2025 Apr. 19];2(S1):S45. Available from: https://skin.dermsquared.com/skin/article/view/301